Evotec SE (ETR:EVT)
Germany · Delayed Price · Currency is EUR 3.502
-0.002 (-0.06%)
Jul 29, 2026, 3:38 PM CET
Evotec SE Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 745.04 | 788.37 | 796.97 | 781.43 | 751.45 | 618.03 |
Revenue Growth | -5.48% | -1.08% | 1.99% | 3.99% | 21.59% | 23.38% |
Gross Profit Gross Profit Growth | 79.42 | 114.22 | 114.88 | 175.05 | 174.07 | 151.54 |
Operating Income Operating Income Growth | -90.13 | -66.03 | -78.92 | -34.13 | 20.85 | 39.23 |
Net Income Net Income Growth | -193.88 | -103.52 | -196.08 | -83.91 | -175.66 | 215.51 |
Earnings Per Share EPS Growth | -1.09 | -0.58 | -1.11 | -0.47 | -0.99 | 1.30 |
EPS Growth | - | - | - | - | - | 3137.72% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Discovery and Preclinical Development Discovery and Preclinical Development Growth | 508.59 | 529.28 | 611.55 | 672.98 | 702.02 | - |
Just - Evotec Biologics Just - Evotec Biologics Growth | 237.04 | 259.59 | 186.62 | 108.45 | 49.43 | - |
Intersegment Elimination Intersegment Elimination Growth | -0.59 | -0.5 | -1.21 | - | - | -139.12 |
Total Total Growth | 745.04 | 788.37 | 796.97 | 781.43 | 751.45 | 618.03 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 444.76 | 476.39 | 396.8 | 604.11 | 718.49 | 858.23 |
Total Debt Total Debt Growth | 387.46 | 447.69 | 439.42 | 626.2 | 506.67 | 512.92 |
Net Cash (Debt) Net Cash Growth | 57.3 | 28.7 | -42.62 | -22.09 | 211.82 | 345.32 |
Net Cash Growth | - | - | - | - | -38.66% | - |
Net Cash Per Share Net Cash Per Share Growth | 0.32 | 0.16 | -0.24 | -0.12 | 1.20 | 2.07 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 18.71 | -9.18 | 18.22 | 36.44 | 205.81 | 122.24 |
Capital Expenditures CapEx Growth | -58.51 | -72.54 | -117.47 | -213.32 | -181.35 | -118.94 |
Free Cash Flow Free Cash Flow Growth | -39.79 | -81.72 | -99.25 | -176.88 | 24.46 | 3.29 |
Free Cash Flow Growth | - | - | - | - | 642.47% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 10.66% | 14.49% | 14.41% | 22.40% | 23.16% | 24.52% |
Operating Margin | -12.10% | -8.38% | -9.90% | -4.37% | 2.77% | 6.35% |
Pretax Margin | -24.04% | -11.01% | -24.34% | -10.31% | -20.49% | 38.34% |
Profit Margin | -26.02% | -13.13% | -24.60% | -10.74% | -23.38% | 34.87% |
FCF Margin | -5.34% | -10.37% | -12.45% | -22.64% | 3.26% | 0.53% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 34.54 |
Forward PE | - | 191.10 | 191.10 | 154.05 | 273.90 | 93.45 |
P/FCF Ratio | - | - | - | - | 110.25 | 2259.99 |
PS Ratio | 0.84 | 1.23 | 1.82 | 4.82 | 3.59 | 12.05 |